Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv 2019 Oct 22;3(20):3132-3135

Date

10/28/2019

Pubmed ID

31648328

Pubmed Central ID

PMC6849956

DOI

10.1182/bloodadvances.2019000526

Scopus ID

2-s2.0-85074915718 (requires institutional sign-in at Scopus site)   18 Citations

Abstract

Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.

Author List

Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM

Author

Timothy Fenske MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Bendamustine Hydrochloride
Child
Child, Preschool
Cyclophosphamide
Dexamethasone
Doxorubicin
Female
Humans
Infant
Infant, Newborn
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell
Male
Prognosis
Rituximab
Treatment Outcome
Vincristine